SCHEMBL7938166

SCHEMBL7938166

C/C=C/c1nc2cc(C)c(C)cc2nc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 2/20 0.40
KDM4E B2RXH2 4/20 0.39
MAPT P10636 3/20 0.39
NPC1 O15118 4/20 0.38
RAB9A P51151 3/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
MAOB P27338 1/20 0.38
MEN1 O00255 1/20 0.37
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37
KMT2A Q03164 1/20 0.37
MCL1 Q07820 1/20 0.37
ATM Q13315 1/20 0.37
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
GLA P06280 1/20 0.35
HPGD P15428 1/20 0.35
NOS2 P35228 1/20 0.33
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7934977 0.84 NOS2 (0.32) NOS2PDE10A
SCHEMBL12574724 0.81 KDM4E (0.50) NQO2KDM4EMAPTRAB9AMEN1
SCHEMBL7937741 0.81 KDM4E (0.50) NQO2KDM4EMAPTRAB9AMEN1
SCHEMBL7927833 0.79 PDE10A (0.48) NQO2KDM4EMAPTNPC1RAB9A
SCHEMBL12708285 0.79 PDE10A (0.48) NQO2KDM4EMAPTNPC1RAB9A
SCHEMBL12574606 0.78 KDM4E (0.43) KDM4EMAPTNPC1RAB9AKMT2A
SCHEMBL7935792 0.78 KDM4E (0.43) KDM4EMAPTNPC1RAB9AKMT2A
SCHEMBL7935213 0.77 CYP3A4 (0.43) NQO2KDM4EMAPTNPC1RAB9A
SCHEMBL12574810 0.76 KDM4E (0.53) NQO2KDM4EMAPTNPC1RAB9A
SCHEMBL12574816 0.76 KDM4E (0.53) NQO2KDM4EMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-06-30 US disclosed
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-06-30 US disclosed
WO-2010027097-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160206-A1 TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE10A, PDE12, PDE9A NQO2 146/4885KDM4E 322/4885MAPT 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.